The EU expects the Johnson & Johnson vaccine to be delayed. Uncertainty about US export policy makes it difficult to say when the vaccine will arrive.
The Belgian-American vaccine has to comply with strict US export regulations. To avoid export barriers, the company will have to prepare doses outside the United States to secure deliveries, and DPA’s sources say this will lead to delays.
The EU has previously received assurances from Washington that shipments to Europe will pass through, but EU sources now say it is not clear whether these promises still apply.
A White House spokesman said there is no export ban but that US citizens are a priority.
On Thursday, the Johnson & Johnson vaccine became the fourth to be approved in the EU. It is administered in just one dose, and, according to clinical tests, it is up to 72% effective.
The EU has already approved the vaccines from Pfizer / BioNTech, Moderna, and AstraZeneca. These are already in use in Norway, although the use of the AstraZeneca vaccine has now been suspended until it has been clarified whether it can lead to serious side effects.
Source: © NTB Scanpix / #Norway Today / #NorwayTodayNews
Do you have a news tip for Norway Today? We want to hear it. Get in touch at [email protected]
Be the first to comment on "Uncertainty surrounding US export policy might delay Johnson & Johnson vaccine exports to Europe"